Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

7.190 -0.160 (-2.18%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 712,027
Open 7.240
Bid (Size) 6.700 (100)
Ask (Size) 8.000 (1,000)
Prev. Close 7.350
Today's Range 6.732 - 7.250
52wk Range 5.680 - 17.50
Shares Outstanding 42,734,644
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Q3 2025 Earnings Beat Estimates and Announces Strategic Pipeline Refocus
Cullinan Therapeutics (CGEM) beat Q3 2025 EPS estimates, announced a strategic pipeline focus, and has cash into 2029. 
Via Chartmill
Topics Earnings
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-42.0%
-42.0%
1 Month
+2.0%
+2.0%
3 Month
+1.4%
+1.4%
6 Month
-9.1%
-9.1%
1 Year
-55.1%
-55.1%

More News

Read More
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations
Via Benzinga
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan (CGEM) Q2 R&D Jumps 68%
Via The Motley Fool
CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Reports Wider Q2 2025 Loss, Misses EPS Estimates Amid Rising R&D Costs
Via Chartmill
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix
Via Stocktwits
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
From Cullinan Therapeutics, Inc.; Taiho Pharmaceutical Co., Ltd.; Taiho Oncology, Inc.
Via GlobeNewswire
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tesla, Nvidia, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Applied Digital Posts Weak Revenue, Joins Allegro MicroSystems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Topics Stocks
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga

Frequently Asked Questions

Is Cullinan Therapeutics, Inc. - Common Stock publicly traded?
Yes, Cullinan Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Cullinan Therapeutics, Inc. - Common Stock trade on?
Cullinan Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cullinan Therapeutics, Inc. - Common Stock?
The ticker symbol for Cullinan Therapeutics, Inc. - Common Stock is CGEM on the Nasdaq Stock Market
What is the current price of Cullinan Therapeutics, Inc. - Common Stock?
The current price of Cullinan Therapeutics, Inc. - Common Stock is 7.190
When was Cullinan Therapeutics, Inc. - Common Stock last traded?
The last trade of Cullinan Therapeutics, Inc. - Common Stock was at 11/07/25 04:00 PM ET
What is the market capitalization of Cullinan Therapeutics, Inc. - Common Stock?
The market capitalization of Cullinan Therapeutics, Inc. - Common Stock is 307.26M
How many shares of Cullinan Therapeutics, Inc. - Common Stock are outstanding?
Cullinan Therapeutics, Inc. - Common Stock has 307M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.